

Issued: 28 March 2012, London, U.K.

GSK publishes historical quarterly restated financial information.

As previously announced, for 2012 GlaxoSmithKline (GSK) will adopt a revised presentation for the analysis of its Pharmaceuticals and Vaccines turnover by product and therapeutic area that identifies revenues from Emerging Markets/Asia Pacific (excluding Australasia) ('EMAP') as a new segment. This replaces the separate Emerging Markets and Asia Pacific segments reported in 2011. Australasia will now be reported in Rest of World, along with Canada, Puerto Rico and other central revenues.

The revised reporting approach is in line with International Financial Reporting Standards (IFRS) that require companies' segment reporting to be representative of the way in which performance is reported internally.

In addition, the classification of certain products has been changed in 2012, including:

- The transfer of the OTC dermatology brands acquired with the Stiefel business from the Pharmaceuticals and Vaccines business to the Consumer Healthcare business in the USA and Europe;
- The creation of a Rare diseases therapy area;
- The transfer of *Zovirax* from the Dermatology therapy area to the Anti-viral therapy area; and
- Consumer Healthcare will be reported in four categories: Total wellness, Oral care, Nutrition and Skin health.

In order to assist future comparability with historical data, this release includes the Pharmaceuticals and Vaccines turnover by product for each quarter since the period ended 31 March 2011, and for the full years 2011 and 2010, presented on a like-for-like basis with the classifications that will be reported in 2012.

On 1 December 2011, GSK announced the introduction of core measures for both operating profit and earnings per share to report the performance of the Group with effect from Q1 2012. The primary purpose is to provide a clearer view of the underlying performance of GSK's core business by removing the volatility created by various items such as the impairment of intangible assets, legal charges and asset disposal gains and losses. As previously announced, the adjustments to be made in arriving at core will be as follows:

- Amortisation and impairment of intangible assets (excluding computer software) and goodwill;
- Major restructuring costs;
- Legal charges;
- Other operating income and disposal of associates, products and businesses;
- Acquisition accounting adjustments for material acquisitions; and
- Tax on adjustments.

It was also announced that with effect from Q1 2012, charges for amortisation and impairment of intangible assets related to marketed products will be reported in cost of sales (previously these were included in SG&A). In order to assist future comparability with historical data, this release includes reconciliations of total results restated (for the above referenced change in the presentation of amortisation and impairment of intangible assets related to marketed products) to core earnings for each quarter since the period ended 31 March 2011 and for the full years 2011 and 2010.

None of the restatements noted above has any impact on earnings per share either for total results or for core earnings.

An Excel version of this data is available on www.gsk.com.

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com

GlaxoSmithKline Enquiries:

| | | | |
|-----------------------------|--------------------|----------------------|------------------|
| UK Media enquiries: | David Mawdsley | +44 (0) 20 8047 5502 | (London) |
| | Stephen Rea | +44 (0) 20 8047 5502 | (London) |
| | Sarah Spencer | +44 (0) 20 8047 5502 | (London) |
| | David Daley | +44 (0) 20 8047 5502 | (London) |
| US Media enquiries: | Kevin Colgan | +1 919 483 2839 | (North Carolina) |
| | Melinda Stubbee | +1 919 483 2839 | (North Carolina) |
| | Sarah Alspach | +1 919 483 2839 | (Washington, DC) |
| | Jennifer Armstrong | +1 919 483 2839 | (Philadelphia) |
| Analyst/Investor enquiries: | Sally Ferguson | +44 (0) 20 8047 5543 | (London) |
| | Tom Curry | +1 215 751 5419 | (Philadelphia) |
| | Gary Davies | +44 (0) 20 8047 5503 | (London) |
| | Jeff McLaughlin | +1 215 751 7002 | (Philadelphia) |
| | Ziba Shamsi | +44 (0) 20 8047 3289 | (London) |

CER growth

In order to illustrate underlying performance, it is the Group’s practice to discuss its results in terms of constant exchange rate (CER) growth. This represents growth calculated as if the exchange rates used to determine the results of overseas companies in Sterling had remained unchanged from those used in the comparative period.

Brand names and partner acknowledgements

Brand names appearing in italics throughout this document are trademarks of GSK or associated companies or used under licence by the Group.

This Announcement does not constitute statutory accounts of the Group within the meaning of sections 434(3) and 435(3) of the Companies Act 2006. The information for 2011 and 2010 has been derived from the full Group accounts published in the Annual Reports 2010 and 2011.

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK’s operations are described under ‘Risk factors’ in the ‘Financial review & risk’ section in the company’s Annual Report 2011 included as exhibit 15.2 to the company’s Annual Report on Form 20-F for 2011.

Registered in England & Wales:
No. 3888792

Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS

Pharmaceuticals and Vaccines turnover
Twelve months ended 31 December 2011

| | Total | | USA | | Europe | | EMAP | | Rest of World | |
|--------------------------------------|---------------|-------------|--------------|-------------|--------------|-------------|--------------|-------------|---------------|-------------|
| | £m | CER% | £m | CER% | £m | CER% | £m | CER% | £m | CER% |
| Respiratory | 7,298 | 2 | 3,301 | 1 | 2,115 | (2) | 779 | 9 | 1,103 | 10 |
| <i>Avamys/Veramyst</i> | 241 | 24 | 62 | (6) | 65 | 14 | 54 | 41 | 60 | 92 |
| <i>Flixonase/Flonase</i> | 138 | (17) | 7 | (78) | 37 | (8) | 49 | 11 | 45 | (2) |
| <i>Flixotide/Flovent</i> | 813 | 3 | 447 | 8 | 151 | (6) | 52 | 7 | 163 | (4) |
| <i>Seretide/Advair</i> | 5,061 | - | 2,475 | (1) | 1,580 | (2) | 379 | 2 | 627 | 8 |
| <i>Serevent</i> | 182 | (9) | 62 | 2 | 85 | (14) | 3 | 52 | 32 | (19) |
| <i>Ventolin</i> | 602 | 17 | 239 | 39 | 141 | (1) | 160 | 14 | 62 | 4 |
| <i>Xyzal</i> | 64 | 85 | - | - | - | - | 16 | 7 | 48 | >100 |
| <i>Zyrtec</i> | 96 | 12 | - | - | - | - | 29 | 36 | 67 | 3 |
| Anti-virals | 842 | (29) | 96 | (73) | 101 | (23) | 357 | 1 | 288 | (16) |
| <i>Hepsera</i> | 127 | (3) | - | - | - | - | 96 | (4) | 31 | 4 |
| <i>Zovirax</i> | 109 | (29) | 11 | (79) | 27 | (4) | 37 | 12 | 34 | (13) |
| <i>Valtrex</i> | 339 | (38) | 72 | (70) | 48 | (31) | 38 | 9 | 181 | (3) |
| <i>Zeffix</i> | 237 | 1 | 11 | (15) | 24 | (8) | 176 | 5 | 26 | (11) |
| Central nervous system | 1,721 | (2) | 474 | (3) | 480 | (12) | 311 | 12 | 456 | 2 |
| <i>Imigran/Imitrex</i> | 210 | (2) | 82 | 12 | 74 | (14) | 7 | (2) | 47 | (4) |
| <i>Lamictal</i> | 536 | 8 | 277 | 12 | 131 | (10) | 71 | 3 | 57 | 60 |
| <i>Requip</i> | 218 | (7) | 42 | (2) | 113 | (18) | 12 | - | 51 | 22 |
| <i>Seroxat/Paxil</i> | 435 | (13) | (3) | <(100) | 66 | (20) | 88 | 7 | 284 | (8) |
| <i>Treximet</i> | 57 | 5 | 57 | 7 | - | - | - | - | - | (100) |
| <i>Wellbutrin</i> | 85 | 6 | 16 | (33) | 45 | 15 | 23 | 35 | 1 | 100 |
| Cardiovascular and urogenital | 2,454 | 8 | 1,527 | 4 | 534 | 8 | 251 | 24 | 142 | 45 |
| <i>Arixtra</i> | 276 | (7) | 147 | (14) | 97 | (3) | 21 | 47 | 11 | (10) |
| <i>Avodart</i> | 748 | 20 | 331 | 2 | 223 | 26 | 69 | 28 | 125 | 92 |
| <i>Coreg</i> | 155 | (6) | 154 | (6) | - | - | - | - | 1 | - |
| <i>Fraxiparine</i> | 234 | 5 | - | - | 162 | 5 | 70 | 29 | 2 | (92) |
| <i>Lovaza</i> | 569 | 12 | 567 | 12 | - | - | - | - | 2 | - |
| <i>Vesicare</i> | 126 | 15 | 126 | 16 | - | - | - | - | - | - |
| Metabolic | 331 | (49) | 90 | (60) | 61 | (62) | 63 | (35) | 117 | (27) |
| <i>Avandia products</i> | 123 | (71) | 91 | (60) | (3) | <(100) | 18 | (70) | 17 | (69) |
| Anti-bacterials | 1,390 | 1 | 54 | (25) | 513 | (5) | 724 | 9 | 99 | - |
| <i>Augmentin</i> | 641 | 4 | - | - | 248 | 3 | 352 | 10 | 41 | (5) |
| Oncology and emesis | 683 | 2 | 268 | (20) | 245 | 22 | 92 | 24 | 78 | 26 |
| <i>Arzerra</i> | 44 | 45 | 31 | 23 | 12 | >100 | - | - | 1 | - |
| <i>Promacta</i> | 75 | >100 | 32 | 36 | 23 | >100 | 5 | - | 15 | >100 |
| <i>Tyverb/Tykerb</i> | 231 | 2 | 64 | (6) | 97 | 2 | 42 | 26 | 28 | (7) |
| <i>Votrient</i> | 100 | >100 | 56 | 76 | 37 | >100 | 7 | - | - | - |
| Vaccines | 3,497 | (19) | 814 | 11 | 1,091 | (36) | 1,012 | (11) | 580 | (26) |
| <i>Boostrix</i> | 192 | 7 | 108 | 2 | 48 | 9 | 9 | (1) | 27 | 35 |
| <i>Cervarix</i> | 506 | >100 | 8 | (31) | 58 | (50) | 94 | 71 | 346 | >100 |
| <i>Fluarix, FluLaval</i> | 230 | (2) | 132 | 25 | 40 | (38) | 34 | (20) | 24 | (2) |
| <i>Hepatitis</i> | 688 | (3) | 293 | (1) | 227 | (7) | 111 | (3) | 57 | (2) |
| <i>Infanrix, Pediarix</i> | 690 | (2) | 163 | 16 | 403 | (7) | 68 | (4) | 56 | (5) |
| <i>Rotarix</i> | 300 | 31 | 110 | 55 | 41 | 8 | 129 | 16 | 20 | >100 |
| <i>Synflorix</i> | 350 | 57 | - | - | 52 | 21 | 292 | 81 | 6 | (78) |
| Dermatologicals | 898 | 8 | 263 | (4) | 157 | 4 | 382 | 26 | 96 | (9) |
| <i>Bactroban</i> | 123 | 6 | 51 | 4 | 28 | 4 | 35 | 10 | 9 | 10 |
| <i>Duac</i> | 109 | (3) | 60 | (6) | 24 | - | 13 | 7 | 12 | (8) |
| Rare diseases | 463 | 12 | 105 | (3) | 139 | (1) | 41 | 47 | 178 | 31 |
| <i>Flolan</i> | 179 | (11) | 37 | (15) | 43 | (37) | 1 | - | 98 | 13 |
| <i>Volibris</i> | 97 | >100 | - | - | 69 | 70 | 5 | >100 | 23 | >100 |
| Other | 966 | 2 | 30 | 29 | 264 | (15) | 456 | 14 | 216 | 1 |
| | 20,543 | (5) | 7,022 | (5) | 5,700 | (13) | 4,468 | 5 | 3,353 | (3) |
| ViiV Healthcare (HIV) | 1,569 | 1 | 660 | 4 | 574 | (3) | 199 | 9 | 136 | (4) |
| <i>Combivir</i> | 322 | (10) | 127 | (8) | 93 | (21) | 83 | 8 | 19 | (29) |
| <i>Epivir</i> | 110 | (3) | 39 | 3 | 32 | (14) | 27 | 13 | 12 | (21) |
| <i>Epzicom/Kivexa</i> | 617 | 12 | 230 | 14 | 272 | 10 | 43 | 13 | 72 | 10 |
| <i>Lexiva</i> | 142 | (7) | 74 | (4) | 45 | (14) | 16 | 23 | 7 | (36) |
| <i>Selzentry</i> | 110 | 39 | 45 | 38 | 51 | 24 | 4 | 100 | 10 | >100 |
| <i>Trizivir</i> | 126 | (11) | 67 | (4) | 50 | (18) | 5 | 25 | 4 | (43) |
| | 22,112 | (4) | | | | | | | | |

Pharmaceuticals and Vaccines turnover
Three months ended 31 December 2011

| | Total | | USA | | Europe | | EMAP | | Rest of World | |
|--------------------------------------|--------------|-------------|--------------|-------------|--------------|-------------|--------------|-------------|---------------|-------------|
| | £m | CER% | £m | CER% | £m | CER% | £m | CER% | £m | CER% |
| Respiratory | 1,957 | 3 | 919 | 7 | 524 | (5) | 212 | 14 | 302 | - |
| <i>Avamys/Veramyst</i> | 55 | 12 | 13 | (18) | 14 | 17 | 15 | 30 | 13 | 38 |
| <i>Flixonase/Flonase</i> | 31 | (16) | 1 | (80) | 8 | (10) | 13 | (8) | 9 | - |
| <i>Flixotide/Flovent</i> | 232 | 7 | 134 | 17 | 37 | (10) | 13 | 16 | 48 | (4) |
| <i>Seretide/Advair</i> | 1,351 | 2 | 682 | 4 | 390 | (5) | 101 | 7 | 178 | 6 |
| <i>Serevent</i> | 44 | (12) | 14 | - | 20 | (17) | 1 | >100 | 9 | (29) |
| <i>Ventolin</i> | 171 | 23 | 72 | 49 | 38 | 3 | 48 | 19 | 13 | (3) |
| <i>Xyzal</i> | 22 | (9) | - | - | - | - | 5 | - | 17 | (11) |
| <i>Zyrtec</i> | 24 | - | - | - | - | - | 9 | 50 | 15 | (18) |
| Anti-virals | 200 | (19) | 11 | (71) | 25 | (17) | 91 | 4 | 73 | (20) |
| <i>Hepsera</i> | 37 | 9 | - | - | - | - | 29 | 13 | 8 | 13 |
| <i>Zovirax</i> | 26 | (33) | - | - | 7 | (14) | 11 | 42 | 8 | (11) |
| <i>Valtrex</i> | 76 | (23) | 6 | (75) | 12 | (27) | 12 | 15 | 46 | (3) |
| <i>Zeffix</i> | 56 | (14) | 3 | (33) | 5 | - | 41 | (13) | 7 | (22) |
| Central/nervous system | 446 | (1) | 121 | 7 | 114 | (12) | 82 | 6 | 129 | - |
| <i>Imigran/Imitrex</i> | 54 | 6 | 20 | 40 | 18 | (5) | 1 | (30) | 15 | (11) |
| <i>Lamictal</i> | 141 | 9 | 70 | 9 | 32 | (6) | 18 | 3 | 21 | 72 |
| <i>Requip</i> | 52 | (13) | 11 | 10 | 22 | (33) | 2 | (35) | 17 | 21 |
| <i>Seroxat/Paxil</i> | 116 | (13) | - | - | 17 | (11) | 22 | 2 | 77 | (17) |
| <i>Treximet</i> | 15 | 7 | 15 | 14 | - | - | - | - | - | - |
| <i>Wellbutrin</i> | 20 | (5) | 3 | (71) | 11 | 9 | 5 | (20) | 1 | - |
| Cardiovascular and urogenital | 645 | 5 | 398 | (2) | 133 | 9 | 70 | 31 | 44 | 21 |
| <i>Arixtra</i> | 56 | (30) | 23 | (51) | 24 | - | 7 | 40 | 2 | (49) |
| <i>Avodart</i> | 206 | 17 | 89 | 6 | 60 | 22 | 18 | 37 | 39 | 33 |
| <i>Coreg</i> | 41 | 2 | 40 | 2 | - | - | - | - | 1 | - |
| <i>Fraxiparine</i> | 60 | 13 | - | - | 39 | 8 | 20 | 15 | 1 | - |
| <i>Lovaza</i> | 158 | 10 | 158 | 10 | - | - | - | - | - | - |
| <i>Vesicare</i> | 32 | 6 | 33 | 10 | - | - | - | - | (1) | - |
| Metabolic | 95 | (8) | 30 | (22) | 14 | 34 | 18 | 50 | 33 | (24) |
| <i>Avandia products</i> | 39 | (20) | 31 | (25) | - | - | 4 | >100 | 4 | (68) |
| Anti-bacterials | 355 | (1) | 6 | (63) | 123 | (18) | 203 | 17 | 23 | 21 |
| <i>Augmentin</i> | 173 | 7 | (1) | - | 63 | (7) | 101 | 19 | 10 | (4) |
| Oncology and emesis | 179 | 8 | 71 | (3) | 61 | 15 | 28 | 47 | 19 | (12) |
| <i>Arzerra</i> | 12 | 33 | 8 | 33 | 3 | - | - | - | 1 | - |
| <i>Promacta</i> | 24 | >100 | 8 | 50 | 8 | >100 | 3 | - | 5 | >100 |
| <i>Tyverb/Tykerb</i> | 59 | - | 17 | - | 22 | (8) | 12 | 25 | 8 | (8) |
| <i>Votrient</i> | 31 | >100 | 16 | 45 | 12 | >100 | 4 | - | (1) | - |
| Vaccines | 810 | (18) | 158 | (6) | 290 | (25) | 238 | (20) | 124 | 1 |
| <i>Boostrix</i> | 45 | (10) | 23 | (18) | 14 | 27 | 1 | (26) | 7 | (33) |
| <i>Cervarix</i> | 100 | 46 | 1 | 100 | 17 | (28) | 26 | 69 | 56 | >100 |
| <i>Fluarix, FluLaval</i> | 54 | (22) | 17 | (39) | 18 | 31 | 13 | (33) | 6 | (15) |
| <i>Hepatitis</i> | 161 | (1) | 59 | 7 | 54 | (14) | 32 | 13 | 16 | 2 |
| <i>Infanrix, Pediarix</i> | 181 | (4) | 32 | (8) | 115 | (3) | 19 | 16 | 15 | (29) |
| <i>Rotarix</i> | 73 | (5) | 25 | 29 | 10 | 22 | 27 | (39) | 11 | >100 |
| <i>Synflorix</i> | 67 | 44 | - | - | 16 | >100 | 49 | 36 | 2 | (78) |
| Dermatologicals | 221 | 2 | 64 | (11) | 39 | 9 | 97 | 16 | 21 | (25) |
| <i>Bactroban</i> | 29 | 3 | 13 | 8 | 6 | (14) | 8 | 10 | 2 | 9 |
| <i>Duac</i> | 26 | 4 | 14 | - | 6 | - | 2 | (1) | 4 | 44 |
| Rare diseases | 126 | 6 | 27 | (11) | 32 | (17) | 13 | 53 | 54 | 30 |
| <i>Flolan</i> | 44 | (16) | 8 | (27) | 9 | (53) | - | - | 27 | 14 |
| <i>Volibris</i> | 28 | 69 | - | - | 17 | 31 | 1 | >100 | 10 | >100 |
| Other | 256 | (11) | 8 | 64 | 75 | (22) | 111 | (3) | 62 | (17) |
| | 5,290 | (3) | 1,813 | - | 1,430 | (11) | 1,163 | 4 | 884 | (3) |
| ViiV Healthcare (HIV) | 402 | 1 | 176 | 10 | 138 | (3) | 50 | (17) | 38 | 11 |
| <i>Combivir</i> | 68 | (29) | 30 | (12) | 19 | (29) | 15 | (41) | 4 | (63) |
| <i>Epivir</i> | 27 | (7) | 9 | - | 7 | (13) | 7 | (13) | 4 | - |
| <i>Epzicom/Kivexa</i> | 170 | 17 | 65 | 20 | 70 | 13 | 13 | 8 | 22 | 31 |
| <i>Lexiva</i> | 38 | 6 | 20 | - | 10 | - | 7 | - | 1 | (50) |
| <i>Selzentry</i> | 33 | 50 | 13 | 44 | 12 | 9 | 2 | 100 | 6 | >100 |
| <i>Trizivir</i> | 32 | 3 | 18 | 13 | 11 | (21) | 2 | - | 1 | - |
| | 5,692 | (3) | | | | | | | | |

Pharmaceuticals and Vaccines turnover
Three months ended 30 September 2011

| | Total | | USA | | Europe | | EMAP | | Rest of World | |
|--------------------------------------|--------------|-------------|--------------|-------------|--------------|-------------|--------------|-----------|---------------|-------------|
| | £m | CER% | £m | CER% | £m | CER% | £m | CER% | £m | CER% |
| Respiratory | 1,714 | (2) | 783 | (6) | 502 | (1) | 184 | 8 | 245 | 7 |
| <i>Avamys/Veramyst</i> | 50 | 23 | 17 | 13 | 13 | 20 | 14 | 39 | 6 | 25 |
| <i>Flixonase/Flonase</i> | 28 | (16) | 2 | (63) | 9 | - | 13 | 30 | 4 | (50) |
| <i>Flixotide/Flovent</i> | 183 | (3) | 100 | (3) | 35 | - | 12 | 28 | 36 | (12) |
| <i>Seretide/Advair</i> | 1,217 | (3) | 593 | (7) | 384 | - | 89 | - | 151 | 8 |
| <i>Serevent</i> | 43 | (10) | 15 | (6) | 21 | (17) | - | - | 7 | - |
| <i>Ventolin</i> | 136 | 5 | 54 | 10 | 32 | (6) | 33 | 6 | 17 | 6 |
| <i>Xyzal</i> | 12 | >100 | - | - | - | - | 4 | - | 8 | - |
| <i>Zyrtec</i> | 21 | 5 | - | - | - | - | 7 | 33 | 14 | (8) |
| Anti-virals | 208 | (13) | 24 | (50) | 25 | (14) | 92 | 9 | 67 | (13) |
| <i>Hepsera</i> | 32 | (6) | - | - | - | - | 24 | (4) | 8 | (14) |
| <i>Zovirax</i> | 25 | (19) | 1 | (88) | 7 | 17 | 10 | 25 | 7 | (20) |
| <i>Valtrex</i> | 87 | (12) | 22 | (19) | 11 | (14) | 9 | 11 | 45 | (11) |
| <i>Zeffix</i> | 63 | 11 | 1 | (33) | 7 | (14) | 48 | 18 | 7 | 17 |
| Central nervous system | 458 | 3 | 140 | 16 | 123 | (11) | 80 | 6 | 115 | 4 |
| <i>Imigran/Imitrex</i> | 54 | - | 21 | 17 | 20 | (14) | 3 | 59 | 10 | (9) |
| <i>Lamictal</i> | 153 | 18 | 88 | 29 | 33 | (9) | 18 | (8) | 14 | >100 |
| <i>Requip</i> | 56 | (7) | 11 | (15) | 29 | (9) | 3 | (26) | 13 | 22 |
| <i>Seroxat/Paxil</i> | 109 | (9) | - | (100) | 16 | (16) | 23 | - | 70 | (3) |
| <i>Treximet</i> | 14 | - | 14 | - | - | - | - | - | - | - |
| <i>Wellbutrin</i> | 23 | 33 | 5 | 50 | 12 | 10 | 8 | >100 | (2) | - |
| Cardiovascular and urogenital | 630 | 8 | 394 | 2 | 136 | 14 | 64 | 28 | 36 | 41 |
| <i>Arixtra</i> | 71 | (3) | 39 | (9) | 23 | 5 | 5 | 25 | 4 | - |
| <i>Avodart</i> | 188 | 19 | 79 | (8) | 58 | 37 | 18 | 26 | 33 | >100 |
| <i>Coreg</i> | 38 | (11) | 39 | (12) | - | - | - | - | (1) | - |
| <i>Fraxiparine</i> | 60 | 7 | - | - | 42 | 18 | 17 | 13 | 1 | (80) |
| <i>Lovaza</i> | 139 | 2 | 139 | 4 | - | - | - | - | - | - |
| <i>Vesicare</i> | 33 | 21 | 32 | 22 | - | - | - | - | 1 | - |
| Metabolic | 75 | (38) | 14 | (55) | 16 | (57) | 15 | 10 | 30 | (24) |
| <i>Avandia products</i> | 22 | (67) | 14 | (52) | (1) | <(100) | 6 | (22) | 3 | (71) |
| Anti-bacterials | 323 | (3) | 13 | - | 112 | (12) | 171 | 3 | 27 | (5) |
| <i>Augmentin</i> | 139 | (10) | (1) | (100) | 54 | (7) | 74 | (9) | 12 | (27) |
| Oncology and emesis | 194 | 13 | 83 | (3) | 65 | 27 | 24 | 21 | 22 | 61 |
| <i>Arzerra</i> | 12 | 33 | 9 | 13 | 3 | >100 | - | - | - | - |
| <i>Promacta</i> | 22 | >100 | 10 | 67 | 6 | >100 | 1 | - | 5 | - |
| <i>Tyverb/Tykerb</i> | 61 | 3 | 19 | 11 | 24 | (4) | 11 | 7 | 7 | 4 |
| <i>Votrient</i> | 30 | >100 | 16 | 89 | 12 | >100 | 2 | - | - | - |
| Vaccines | 1,142 | 14 | 323 | 20 | 285 | (12) | 283 | 4 | 251 | 88 |
| <i>Boostrix</i> | 62 | 7 | 43 | 10 | 13 | - | 2 | (23) | 4 | 22 |
| <i>Cervarix</i> | 232 | >100 | 4 | (25) | 12 | - | 29 | 65 | 187 | >100 |
| <i>Fluarix, FluLaval</i> | 159 | (2) | 109 | 40 | 24 | (52) | 12 | (46) | 14 | 7 |
| <i>Hepatitis</i> | 178 | (6) | 82 | (14) | 55 | (4) | 30 | 12 | 11 | 17 |
| <i>Infanrix, Pediarix</i> | 192 | 12 | 60 | 61 | 97 | (4) | 18 | (16) | 17 | 34 |
| <i>Rotarix</i> | 75 | 44 | 25 | 47 | 11 | 25 | 34 | 47 | 5 | 62 |
| <i>Synflorix</i> | 107 | 14 | - | - | 11 | 11 | 95 | 17 | 1 | (47) |
| Dermatologicals | 240 | 10 | 76 | (1) | 40 | (1) | 97 | 23 | 27 | 17 |
| <i>Bactroban</i> | 36 | 9 | 16 | 14 | 8 | 14 | 9 | (2) | 3 | 10 |
| <i>Duac</i> | 30 | (12) | 17 | (15) | 6 | - | 4 | 28 | 3 | (46) |
| Rare diseases | 116 | 10 | 28 | (4) | 34 | (6) | 11 | 85 | 43 | 29 |
| <i>Flolan</i> | 43 | (21) | 10 | (21) | 9 | (47) | - | - | 24 | 1 |
| <i>Volibris</i> | 25 | >100 | - | - | 18 | 70 | 2 | 47 | 5 | >100 |
| Other | 222 | (2) | 11 | 13 | 57 | (12) | 110 | 2 | 44 | 1 |
| | 5,322 | 3 | 1,889 | (1) | 1,395 | (5) | 1,131 | 8 | 907 | 20 |
| ViiV Healthcare (HIV) | 435 | 7 | 177 | 11 | 145 | 1 | 79 | 17 | 34 | (6) |
| <i>Combivir</i> | 112 | 17 | 37 | 8 | 22 | (19) | 47 | 62 | 6 | - |
| <i>Epivir</i> | 28 | (10) | 10 | - | 8 | (11) | 8 | - | 2 | (50) |
| <i>Epzicom/Kivexa</i> | 160 | 14 | 61 | 26 | 69 | 16 | 13 | (7) | 17 | (12) |
| <i>Lexiva</i> | 35 | (13) | 19 | 5 | 11 | (23) | 2 | (57) | 3 | 100 |
| <i>Selzentry</i> | 28 | 40 | 12 | 63 | 14 | 40 | 1 | - | 1 | (100) |
| <i>Trizivir</i> | 33 | (16) | 17 | (5) | 13 | (20) | 2 | (33) | 1 | (100) |
| | 5,757 | 3 | | | | | | | | |

Pharmaceuticals and Vaccines turnover
Three months ended 30 June 2011

| | Total | | USA | | Europe | | EMAP | | Rest of World | |
|--------------------------------------|--------------|-------------|--------------|-------------|--------------|-------------|--------------|-------------|---------------|-------------|
| | £m | CER% | £m | CER% | £m | CER% | £m | CER% | £m | CER% |
| Respiratory | 1,812 | 2 | 808 | 2 | 552 | 1 | 199 | 6 | 253 | 7 |
| <i>Avamys/Veramyst</i> | 64 | 14 | 17 | (5) | 22 | 5 | 15 | 45 | 10 | 59 |
| <i>Flixonase/Flonase</i> | 31 | (36) | 1 | (94) | 11 | (17) | 13 | 27 | 6 | (22) |
| <i>Flixotide/Flovent</i> | 196 | 1 | 106 | 6 | 39 | (3) | 12 | 1 | 39 | (5) |
| <i>Seretide/Advair</i> | 1,270 | 2 | 614 | 2 | 407 | 2 | 97 | 2 | 152 | 5 |
| <i>Serevent</i> | 43 | (17) | 12 | (24) | 22 | (8) | - | - | 9 | (11) |
| <i>Ventolin</i> | 149 | 15 | 57 | 38 | 35 | - | 40 | 7 | 17 | 3 |
| <i>Xyzal</i> | 15 | >100 | - | - | - | - | 4 | (20) | 11 | - |
| <i>Zyrtec</i> | 20 | - | - | - | - | - | 6 | - | 14 | - |
| Anti-virals | 214 | (29) | 24 | (75) | 26 | (19) | 97 | 12 | 67 | (13) |
| <i>Hepsera</i> | 30 | (9) | - | - | - | - | 22 | (12) | 8 | - |
| <i>Zovirax</i> | 22 | (33) | (1) | - | 6 | (14) | 9 | - | 8 | (35) |
| <i>Valtrex</i> | 86 | (48) | 22 | (74) | 13 | (25) | 9 | (11) | 42 | (9) |
| <i>Zeffix</i> | 62 | 3 | 3 | (25) | 6 | - | 47 | 11 | 6 | (26) |
| Central nervous system | 421 | (6) | 110 | (9) | 123 | (12) | 74 | 13 | 114 | (5) |
| <i>Imigran/Imitrex</i> | 51 | (2) | 20 | 11 | 19 | (14) | 1 | (38) | 11 | 5 |
| <i>Lamictal</i> | 128 | 7 | 66 | 20 | 33 | (16) | 17 | 1 | 12 | 35 |
| <i>Requip</i> | 57 | (5) | 10 | - | 32 | (17) | 4 | 36 | 11 | 19 |
| <i>Seroxat/Paxil</i> | 107 | (21) | (4) | - | 17 | (27) | 20 | 1 | 74 | (8) |
| <i>Treximet</i> | 14 | (6) | 14 | - | - | - | - | - | - | (100) |
| <i>Wellbutrin</i> | 23 | 5 | 5 | (20) | 12 | 33 | 5 | 20 | 1 | (100) |
| Cardiovascular and urogenital | 636 | 13 | 401 | 11 | 138 | 5 | 63 | 20 | 34 | 75 |
| <i>Arixtra</i> | 75 | (1) | 41 | (2) | 26 | (7) | 5 | - | 3 | (33) |
| <i>Avodart</i> | 188 | 24 | 87 | 8 | 55 | 20 | 18 | 26 | 28 | >100 |
| <i>Coreg</i> | 39 | (5) | 38 | (5) | - | - | - | - | 1 | - |
| <i>Fraxiparine</i> | 60 | 4 | - | - | 42 | 3 | 18 | 27 | - | - |
| <i>Lovaza</i> | 145 | 14 | 144 | 13 | - | - | - | - | 1 | - |
| <i>Vesicare</i> | 33 | 17 | 33 | 17 | - | - | - | - | - | - |
| Metabolic | 77 | (62) | 20 | (71) | 16 | (73) | 15 | (61) | 26 | (29) |
| <i>Avandia products</i> | 26 | (82) | 20 | (72) | (2) | - | 3 | (88) | 5 | (66) |
| Anti-bacterials | 333 | - | 16 | (19) | 122 | (3) | 170 | 4 | 25 | 4 |
| <i>Augmentin</i> | 142 | - | (1) | - | 56 | 4 | 79 | 4 | 8 | (10) |
| Oncology and emesis | 162 | (5) | 56 | (33) | 63 | 33 | 22 | 12 | 21 | 39 |
| <i>Arzerra</i> | 11 | 38 | 7 | 14 | 3 | - | - | - | 1 | - |
| <i>Promacta</i> | 17 | >100 | 8 | 29 | 5 | >100 | 1 | - | 3 | - |
| <i>Tyverb/Tykerb</i> | 59 | 7 | 15 | (11) | 27 | 23 | 11 | 51 | 6 | (33) |
| <i>Votrient</i> | 22 | >100 | 12 | 63 | 8 | - | 1 | - | 1 | - |
| Vaccines | 787 | (15) | 178 | 36 | 275 | (27) | 254 | 7 | 80 | (61) |
| <i>Boostrix</i> | 53 | 26 | 27 | 12 | 12 | 9 | 4 | >100 | 10 | 80 |
| <i>Cervarix</i> | 65 | 30 | 2 | (50) | 14 | (33) | 17 | 36 | 32 | >100 |
| <i>Fluarix, FluLaval</i> | 8 | - | 5 | - | (2) | - | 4 | >100 | 1 | - |
| <i>Hepatitis</i> | 191 | 15 | 82 | 47 | 64 | (2) | 31 | (1) | 14 | (19) |
| <i>Infanrix, Pediarix</i> | 156 | (11) | 31 | (13) | 100 | (12) | 13 | (17) | 12 | 12 |
| <i>Rotarix</i> | 75 | >100 | 33 | >100 | 10 | 25 | 31 | 56 | 1 | 33 |
| <i>Synflorix</i> | 99 | >100 | - | - | 12 | (14) | 83 | >100 | 4 | (74) |
| Dermatologicals | 221 | 11 | 60 | 3 | 41 | 7 | 98 | 36 | 22 | (30) |
| <i>Bactroban</i> | 30 | 3 | 11 | (7) | 7 | - | 10 | 24 | 2 | 11 |
| <i>Duac</i> | 25 | (7) | 13 | - | 6 | - | 3 | 1 | 3 | (37) |
| Rare diseases | 110 | 12 | 24 | (8) | 35 | 8 | 7 | 11 | 44 | 36 |
| <i>Flolan</i> | 45 | (8) | 9 | (17) | 11 | (31) | 1 | (8) | 24 | 15 |
| <i>Volibris</i> | 22 | >100 | - | - | 17 | 89 | - | - | 5 | >100 |
| Other | 269 | 18 | 8 | 13 | 67 | (19) | 125 | 41 | 69 | 32 |
| | 5,042 | (4) | 1,705 | (4) | 1,458 | (9) | 1,124 | 11 | 755 | (11) |
| ViiV Healthcare (HIV) | 379 | - | 154 | (4) | 146 | (3) | 45 | 61 | 34 | (18) |
| <i>Combivir</i> | 71 | (16) | 30 | (18) | 25 | (20) | 12 | 9 | 4 | (29) |
| <i>Epivir</i> | 29 | 11 | 9 | (10) | 8 | (20) | 9 | >100 | 3 | 33 |
| <i>Epzicom/Kivexa</i> | 147 | 7 | 53 | 2 | 68 | 8 | 10 | 25 | 16 | 14 |
| <i>Lexiva</i> | 37 | - | 18 | (5) | 12 | (8) | 6 | >100 | 1 | (67) |
| <i>Selzentry</i> | 26 | 37 | 10 | 22 | 13 | 30 | 1 | - | 2 | >100 |
| <i>Trizivir</i> | 31 | (8) | 17 | - | 13 | (7) | 1 | - | - | - |
| | 5,421 | (3) | | | | | | | | |

Pharmaceuticals and Vaccines turnover
Three months ended 31 March 2011

| | Total | | USA | | Europe | | EMAP | | Rest of World | |
|--------------------------------------|--------------|-------------|--------------|-------------|--------------|-------------|--------------|-------------|---------------|-------------|
| | £m | CER% | £m | CER% | £m | CER% | £m | CER% | £m | CER% |
| Respiratory | 1,815 | 3 | 791 | 1 | 537 | (4) | 184 | 8 | 303 | 28 |
| <i>Avamys/Veramyst</i> | 72 | 52 | 15 | (12) | 16 | 23 | 10 | 57 | 31 | >100 |
| <i>Flixonase/Flonase</i> | 48 | 2 | 3 | (50) | 9 | - | 10 | - | 26 | 21 |
| <i>Flixotide/Flovent</i> | 202 | 4 | 107 | 11 | 40 | (9) | 15 | (8) | 40 | 6 |
| <i>Seretide/Advair</i> | 1,223 | (2) | 586 | (5) | 399 | (4) | 92 | (2) | 146 | 17 |
| <i>Serevent</i> | 52 | 2 | 21 | 38 | 22 | (15) | 2 | - | 7 | (32) |
| <i>Ventolin</i> | 146 | 27 | 56 | 66 | 36 | (3) | 39 | 25 | 15 | 10 |
| <i>Xyzal</i> | 15 | >100 | - | - | - | - | 3 | >100 | 12 | >100 |
| <i>Zyrtec</i> | 31 | 45 | - | - | - | - | 7 | 75 | 24 | 38 |
| Anti-virals | 220 | (45) | 37 | (77) | 25 | (35) | 77 | (20) | 81 | (16) |
| <i>Hepsera</i> | 28 | (7) | - | - | - | - | 21 | (13) | 7 | 20 |
| <i>Zovirax</i> | 36 | (29) | 11 | (58) | 7 | - | 7 | (12) | 11 | 26 |
| <i>Valtrex</i> | 90 | (51) | 22 | (79) | 12 | (48) | 8 | 28 | 48 | 11 |
| <i>Zeffix</i> | 56 | 6 | 4 | 33 | 6 | (14) | 40 | 8 | 6 | - |
| Central nervous system | 396 | (6) | 103 | (23) | 120 | (14) | 75 | 27 | 98 | 11 |
| <i>Imigran/Imitrex</i> | 51 | (12) | 21 | (8) | 17 | (23) | 2 | (3) | 11 | 1 |
| <i>Lamictal</i> | 114 | (4) | 53 | (11) | 33 | (8) | 18 | 19 | 10 | 31 |
| <i>Requip</i> | 53 | (4) | 10 | - | 30 | (14) | 3 | 54 | 10 | 28 |
| <i>Seroxat/Paxil</i> | 103 | (8) | 1 | (90) | 16 | (23) | 23 | 30 | 63 | 1 |
| <i>Treximet</i> | 14 | 15 | 14 | 15 | - | - | - | - | - | - |
| <i>Wellbutrin</i> | 19 | (5) | 3 | (50) | 10 | 11 | 5 | 25 | 1 | (100) |
| Cardiovascular and urogenital | 543 | 8 | 334 | 5 | 127 | 6 | 54 | 17 | 28 | 56 |
| <i>Arixtra</i> | 74 | 9 | 44 | 15 | 24 | (8) | 4 | 33 | 2 | 50 |
| <i>Avodart</i> | 166 | 20 | 76 | 3 | 50 | 28 | 15 | 24 | 25 | >100 |
| <i>Coreg</i> | 37 | (10) | 37 | (10) | - | - | - | - | - | - |
| <i>Fraxiparine</i> | 54 | (2) | - | - | 39 | (7) | 15 | 36 | - | - |
| <i>Lovaza</i> | 127 | 22 | 126 | 21 | - | - | - | - | 1 | - |
| <i>Vesicare</i> | 28 | 16 | 28 | 16 | - | - | - | - | - | - |
| Metabolic | 84 | (62) | 26 | (70) | 15 | (73) | 15 | (57) | 28 | (31) |
| <i>Avandia products</i> | 36 | (79) | 26 | (70) | - | - | 5 | (82) | 5 | (73) |
| Anti-bacterials | 379 | 8 | 19 | (21) | 156 | 12 | 180 | 13 | 24 | (13) |
| <i>Augmentin</i> | 187 | 19 | 3 | (63) | 75 | 21 | 98 | 27 | 11 | 21 |
| Oncology and emesis | 148 | (10) | 58 | (35) | 56 | 16 | 18 | 15 | 16 | 41 |
| <i>Arzerra</i> | 9 | 100 | 7 | 40 | 3 | - | - | - | (1) | - |
| <i>Promacta</i> | 12 | 100 | 6 | - | 4 | - | - | - | 2 | - |
| <i>Tyverb/Tykerb</i> | 52 | (2) | 13 | (24) | 24 | - | 8 | 30 | 7 | 20 |
| <i>Votrient</i> | 17 | >100 | 12 | >100 | 5 | - | - | - | - | - |
| Vaccines | 758 | (46) | 155 | (7) | 241 | (60) | 237 | (27) | 125 | (62) |
| <i>Boostrix</i> | 32 | 7 | 15 | - | 9 | - | 2 | (38) | 6 | 89 |
| <i>Cervarix</i> | 109 | 34 | 1 | (50) | 15 | (75) | 22 | >100 | 71 | >100 |
| <i>Fluarix, FluLaval</i> | 9 | 60 | 1 | - | - | - | 5 | - | 3 | (58) |
| <i>Hepatitis</i> | 158 | (19) | 70 | (23) | 54 | (10) | 18 | (34) | 16 | (3) |
| <i>Infanrix, Pediarix</i> | 161 | (2) | 40 | 28 | 91 | (11) | 18 | 7 | 12 | (20) |
| <i>Rotarix</i> | 77 | 20 | 27 | 4 | 10 | (23) | 37 | 67 | 3 | 17 |
| <i>Synflorix</i> | 77 | 73 | - | - | 13 | 8 | 65 | >100 | (1) | (98) |
| Dermatologicals | 216 | 10 | 63 | (8) | 37 | (1) | 90 | 31 | 26 | 12 |
| <i>Bactroban</i> | 28 | 7 | 11 | - | 7 | 17 | 8 | 10 | 2 | 10 |
| <i>Duac</i> | 28 | 4 | 16 | (6) | 6 | - | 4 | (2) | 2 | >100 |
| Rare diseases | 111 | 21 | 26 | 13 | 38 | 15 | 10 | 45 | 37 | 32 |
| <i>Flolan</i> | 47 | 5 | 10 | 11 | 14 | (18) | - | - | 23 | 24 |
| <i>Volibris</i> | 22 | >100 | - | - | 17 | >100 | 2 | - | 3 | >100 |
| Other | 219 | 8 | 3 | 31 | 65 | (1) | 110 | 24 | 41 | (13) |
| | 4,889 | (14) | 1,615 | (13) | 1,417 | (23) | 1,050 | (2) | 807 | (14) |
| ViiV Healthcare (HIV) | 353 | (4) | 153 | (1) | 145 | (7) | 25 | (8) | 30 | (3) |
| <i>Combivir</i> | 71 | (12) | 30 | (9) | 27 | (18) | 9 | (10) | 5 | - |
| <i>Epivir</i> | 26 | (7) | 11 | 20 | 9 | (10) | 3 | (25) | 3 | (50) |
| <i>Epzicom/Kivexa</i> | 140 | 8 | 51 | 8 | 65 | 3 | 7 | 75 | 17 | 7 |
| <i>Lexiva</i> | 32 | (20) | 17 | (14) | 12 | (20) | 1 | (50) | 2 | (33) |
| <i>Selzentry</i> | 23 | 26 | 10 | 25 | 12 | 20 | - | - | 1 | 100 |
| <i>Trizivir</i> | 30 | (21) | 15 | (21) | 13 | (24) | - | - | 2 | 100 |
| | 5,242 | (14) | | | | | | | | |

Pharmaceuticals and Vaccines turnover
Twelve months ended 31 December 2010

| | Total | USA | Europe | EMAP | Rest of World |
|--------------------------------------|---------------|--------------|--------------|--------------|---------------|
| | £m | £m | £m | £m | £m |
| Respiratory | 7,238 | 3,394 | 2,149 | 735 | 960 |
| <i>Avamys/Veramyst</i> | 193 | 69 | 56 | 38 | 30 |
| <i>Flixonase/Flonase</i> | 164 | 37 | 40 | 44 | 43 |
| <i>Flixotide/Flovent</i> | 804 | 431 | 159 | 51 | 163 |
| <i>Seretide/Advair</i> | 5,139 | 2,604 | 1,601 | 384 | 550 |
| <i>Serevent</i> | 201 | 64 | 98 | 2 | 37 |
| <i>Ventolin</i> | 522 | 179 | 142 | 145 | 56 |
| <i>Xyzal</i> | 33 | - | - | 15 | 18 |
| <i>Zyrtec</i> | 82 | - | - | 22 | 60 |
| Anti-virals | 1,167 | 361 | 128 | 352 | 326 |
| <i>Hepsera</i> | 128 | - | 1 | 99 | 28 |
| <i>Zovirax</i> | 152 | 53 | 27 | 33 | 39 |
| <i>Valtrex</i> | 532 | 252 | 68 | 35 | 177 |
| <i>Zeffix</i> | 233 | 13 | 26 | 166 | 28 |
| Central nervous system | 1,753 | 505 | 540 | 282 | 426 |
| <i>Imigran/Imitrex</i> | 212 | 75 | 85 | 7 | 45 |
| <i>Lamictal</i> | 504 | 257 | 143 | 71 | 33 |
| <i>Requip</i> | 233 | 44 | 137 | 12 | 40 |
| <i>Seroxat/Paxil</i> | 482 | 27 | 82 | 82 | 291 |
| <i>Treximet</i> | 56 | 55 | - | - | 1 |
| <i>Wellbutrin</i> | 81 | 24 | 39 | 17 | 1 |
| Cardiovascular and urogenital | 2,314 | 1,525 | 488 | 206 | 95 |
| <i>Arixtra</i> | 301 | 177 | 99 | 15 | 10 |
| <i>Avodart</i> | 629 | 337 | 175 | 56 | 61 |
| <i>Coreg</i> | 171 | 170 | - | - | 1 |
| <i>Fraxiparine</i> | 222 | - | 154 | 56 | 12 |
| <i>Lovaza</i> | 530 | 528 | - | - | 2 |
| <i>Vesicare</i> | 114 | 113 | - | - | 1 |
| Metabolic | 647 | 237 | 160 | 100 | 150 |
| <i>Avandia products</i> | 440 | 237 | 88 | 61 | 54 |
| Anti-bacterials | 1,396 | 75 | 536 | 689 | 96 |
| <i>Augmentin</i> | 625 | 11 | 240 | 332 | 42 |
| Oncology and emesis | 679 | 346 | 198 | 75 | 60 |
| <i>Arzerra</i> | 31 | 26 | 4 | - | 1 |
| <i>Promacta</i> | 31 | 25 | 5 | - | 1 |
| <i>Tyverb/Tykerb</i> | 227 | 70 | 94 | 35 | 28 |
| <i>Votrient</i> | 38 | 33 | 4 | - | 1 |
| Vaccines | 4,326 | 763 | 1,681 | 1,144 | 738 |
| <i>Boostrix</i> | 181 | 110 | 43 | 10 | 18 |
| <i>Cervarix</i> | 242 | 13 | 116 | 55 | 58 |
| <i>Fluarix, FluLaval</i> | 241 | 110 | 63 | 44 | 24 |
| <i>Hepatitis</i> | 720 | 307 | 242 | 115 | 56 |
| <i>Infanrix, Pediarix</i> | 700 | 146 | 429 | 72 | 53 |
| <i>Rotarix</i> | 235 | 74 | 38 | 115 | 8 |
| <i>Synflorix</i> | 221 | - | 43 | 160 | 18 |
| Dermatologicals | 849 | 286 | 152 | 312 | 99 |
| <i>Bactroban</i> | 119 | 51 | 27 | 34 | 7 |
| <i>Duac</i> | 116 | 67 | 23 | 13 | 13 |
| Rare diseases | 408 | 113 | 138 | 29 | 128 |
| <i>Flolan</i> | 195 | 46 | 67 | - | 82 |
| <i>Volibris</i> | 46 | - | 40 | 1 | 5 |
| Other | 956 | 24 | 309 | 423 | 200 |
| | 21,733 | 7,629 | 6,479 | 4,347 | 3,278 |
| ViiV Healthcare (HIV) | 1,566 | 660 | 585 | 182 | 139 |
| <i>Combivir</i> | 363 | 143 | 117 | 79 | 24 |
| <i>Epivir</i> | 115 | 40 | 37 | 24 | 14 |
| <i>Epzicom/Kivexa</i> | 555 | 210 | 245 | 38 | 62 |
| <i>Lexiva</i> | 155 | 80 | 51 | 13 | 11 |
| <i>Selzentry</i> | 80 | 34 | 41 | 2 | 3 |
| <i>Trizivir</i> | 144 | 73 | 60 | 4 | 7 |
| | 23,299 | | | | |

**Consumer Healthcare turnover
Twelve months ended 31 December 2011**

| | £m | CER% |
|----------------|--------------|----------|
| Total wellness | 2,191 | - |
| Oral care | 1,717 | 8 |
| Nutrition | 1,025 | 10 |
| Skin health | 342 | 1 |
| Total | 5,275 | 5 |
| USA | 1,005 | (1) |
| Europe | 1,997 | (2) |
| ROW | 2,273 | 14 |
| Total | 5,275 | 5 |

**Consumer Healthcare turnover
Three months ended 31 December 2011**

| | £m | CER% |
|----------------|--------------|----------|
| Total wellness | 562 | (2) |
| Oral care | 420 | 4 |
| Nutrition | 223 | 12 |
| Skin health | 81 | (5) |
| Total | 1,286 | 2 |
| USA | 262 | (7) |
| Europe | 490 | (5) |
| ROW | 534 | 14 |
| Total | 1,286 | 2 |

**Consumer Healthcare turnover
Three months ended 30 September 2011**

| | £m | CER% |
|----------------|--------------|----------|
| Total wellness | 540 | - |
| Oral care | 446 | 10 |
| Nutrition | 277 | 9 |
| Skin health | 84 | (4) |
| Total | 1,347 | 5 |
| USA | 259 | 4 |
| Europe | 505 | (3) |
| ROW | 583 | 13 |
| Total | 1,347 | 5 |

**Consumer Healthcare turnover
Three months ended 30 June 2011**

| | £m | CER% |
|----------------|--------------|----------|
| Total wellness | 516 | - |
| Oral care | 425 | 5 |
| Nutrition | 271 | 12 |
| Skin health | 87 | 2 |
| Total | 1,299 | 4 |
| USA | 239 | (2) |
| Europe | 509 | (3) |
| ROW | 551 | 15 |
| Total | 1,299 | 4 |

**Consumer Healthcare turnover
Three months ended 31 March 2011**

| | £m | CER% |
|----------------|--------------|----------|
| Total wellness | 573 | 2 |
| Oral care | 426 | 12 |
| Nutrition | 254 | 9 |
| Skin health | 90 | 10 |
| Total | 1,343 | 7 |
| USA | 245 | 1 |
| Europe | 493 | 2 |
| ROW | 605 | 15 |
| Total | 1,343 | 7 |

**Consumer Healthcare turnover
Twelve months ended 31 December 2010**

| | £m |
|----------------|--------------|
| Total wellness | 2,202 |
| Oral care | 1,596 |
| Nutrition | 953 |
| Skin health | 342 |
| Total | 5,093 |
| USA | 1,056 |
| Europe | 2,027 |
| ROW | 2,010 |
| Total | 5,093 |

Income statement – Core earnings reconciliation
Year ended 31 December 2011

| | Total results (restated) £m | Intangible amortisation £m | Intangible impairment £m | Major restructuring £m | Legal costs £m | Other operating income £m | Core results £m |
|--|-----------------------------------|----------------------------------|--------------------------------|------------------------------|----------------------|------------------------------------|-----------------------|
| Turnover | 27,387 | | | | | | 27,387 |
| Cost of sales | (7,648) | 304 | 12 | 73 | | | (7,259) |
| Gross profit | 19,739 | 304 | 12 | 73 | | | 20,128 |
| Selling, general and administration | (8,510) | | | 397 | 157 | | (7,956) |
| Research and development | (4,009) | 137 | 97 | 97 | | | (3,678) |
| Royalty income | 309 | | | | | | 309 |
| Other operating income | 278 | | | 23 | | (301) | - |
| Operating profit | 7,807 | 441 | 109 | 590 | 157 | (301) | 8,803 |
| Net finance costs | (709) | | | 2 | | | (707) |
| Profit on disposal of interest in associates | 585 | | | | | (585) | - |
| Share of after tax profits of associates and joint ventures | 15 | | | | | | 15 |
| Profit before taxation | 7,698 | 441 | 109 | 592 | 157 | (886) | 8,111 |
| Taxation | (2,240) | (137) | (41) | (114) | (22) | 450 | (2,104) |
| <i>Tax rate %</i> | <i>29.1%</i> | | | | | | <i>25.9%</i> |
| Profit after taxation | 5,458 | 304 | 68 | 478 | 135 | (436) | 6,007 |
| Profit attributable to non-controlling interests | 197 | | | | | | 197 |
| Profit attributable to shareholders | 5,261 | 304 | 68 | 478 | 135 | (436) | 5,810 |
| Earnings per share | 104.6p | 6.0p | 1.4p | 9.5p | 2.7p | (8.7)p | 115.5p |
| Weighted average number of shares (millions) | 5,028 | | | | | | 5,028 |

**Income statement – Core earnings reconciliation
Three months ended 31 December 2011**

| | Total results (restated) £m | Intangible amortisation £m | Intangible impairment £m | Major restructuring £m | Legal costs £m | Other operating income £m | Core results £m |
|--|--------------------------------------|----------------------------------|--------------------------------|------------------------------|----------------------|------------------------------------|-----------------------|
| Turnover | 6,978 | | | | | | 6,978 |
| Cost of sales | (1,949) | 67 | (13) | 19 | | | (1,876) |
| Gross profit | 5,029 | 67 | (13) | 19 | | | 5,102 |
| Selling, general and administration | (2,172) | | | 162 | 76 | | (1,934) |
| Research and development | (1,095) | 33 | 71 | (4) | | | (995) |
| Royalty income | 91 | | | | | | 91 |
| Other operating income | 26 | | | 23 | | (49) | - |
| Operating profit | 1,879 | 100 | 58 | 200 | 76 | (49) | 2,264 |
| Net finance costs | (175) | | | 1 | | | (174) |
| Profit on disposal of interest in associates | 1 | | | | | (1) | - |
| Share of after tax profits of associates and joint ventures | (4) | | | | | | (4) |
| Profit before taxation | 1,701 | 100 | 58 | 201 | 76 | (50) | 2,086 |
| Taxation | (417) | (30) | (25) | (46) | (10) | 24 | (504) |
| <i>Tax rate %</i> | <i>24.5%</i> | | | | | | <i>24.2%</i> |
| Profit after taxation | 1,284 | 70 | 33 | 155 | 66 | (26) | 1,582 |
| Profit attributable to non-controlling interests | 32 | | | | | | 32 |
| Profit attributable to shareholders | 1,252 | 70 | 33 | 155 | 66 | (26) | 1,550 |
| Earnings per share | 25.2p | 1.4p | 0.7p | 3.1p | 1.3p | (0.5)p | 31.2p |
| Weighted average number of shares (millions) | 4,962 | | | | | | 4,962 |

Income statement – Core earnings reconciliation
Three months ended 30 September 2011

| | Total results (restated) £m | Intangible amortisation £m | Intangible impairment £m | Major restructuring £m | Legal costs £m | Other operating income £m | Core results £m |
|--|--------------------------------------|----------------------------------|--------------------------------|------------------------------|----------------------|------------------------------------|-----------------------|
| Turnover | 7,104 | | | | | | 7,104 |
| Cost of sales | (2,083) | 84 | 1 | 20 | | | (1,978) |
| Gross profit | 5,021 | 84 | 1 | 20 | | | 5,126 |
| Selling, general and administration | (2,013) | | | 31 | 20 | | (1,962) |
| Research and development | (984) | 34 | 16 | 13 | | | (921) |
| Royalty income | 85 | | | | | | 85 |
| Other operating income | 6 | | | | | (6) | - |
| Operating profit | 2,115 | 118 | 17 | 64 | 20 | (6) | 2,328 |
| Net finance costs | (172) | | | 1 | | | (171) |
| Profit on disposal of interest in associates | - | | | | | | - |
| Share of after tax profits of associates and joint ventures | (2) | | | | | | (2) |
| Profit before taxation | 1,941 | 118 | 17 | 65 | 20 | (6) | 2,155 |
| Taxation | (498) | (37) | (6) | (17) | (3) | 2 | (559) |
| <i>Tax rate %</i> | <i>25.7%</i> | | | | | | 25.9% |
| Profit after taxation | 1,443 | 81 | 11 | 48 | 17 | (4) | 1,596 |
| Profit attributable to non-controlling interests | 65 | | | | | | 65 |
| Profit attributable to shareholders | 1,378 | 81 | 11 | 48 | 17 | (4) | 1,531 |
| Earnings per share | 27.6p | 1.6p | 0.2p | 0.9p | 0.3p | - | 30.6p |
| Weighted average number of shares (millions) | 5,001 | | | | | | 5,001 |

**Income statement – Core earnings reconciliation
Three months ended 30 June 2011**

| | Total results (restated) £m | Intangible amortisation £m | Intangible impairment £m | Major restructuring £m | Legal costs £m | Other operating income £m | Core results £m |
|--|--------------------------------------|----------------------------------|--------------------------------|------------------------------|----------------------|------------------------------------|-----------------------|
| Turnover | 6,720 | | | | | | 6,720 |
| Cost of sales | (1,744) | 76 | 24 | 19 | | | (1,625) |
| Gross profit | 4,976 | 76 | 24 | 19 | | | 5,095 |
| Selling, general and administration | (2,245) | | | 101 | 61 | | (2,083) |
| Research and development | (1,015) | 36 | 2 | 71 | | | (906) |
| Royalty income | 61 | | | | | | 61 |
| Other operating income | 1 | | | | | (1) | - |
| Operating profit | 1,778 | 112 | 26 | 191 | 61 | (1) | 2,167 |
| Net finance costs | (188) | | | | | | (188) |
| Profit on disposal of interest in associates | - | | | | | | - |
| Share of after tax profits of associates and joint ventures | 2 | | | | | | 2 |
| Profit before taxation | 1,592 | 112 | 26 | 191 | 61 | (1) | 1,981 |
| Taxation | (445) | (35) | (8) | (30) | (9) | | (527) |
| <i>Tax rate %</i> | <i>28.0%</i> | | | | | | <i>26.6%</i> |
| Profit after taxation | 1,147 | 77 | 18 | 161 | 52 | (1) | 1,454 |
| Profit attributable to non-controlling interests | 41 | | | | | | 41 |
| Profit attributable to shareholders | 1,106 | 77 | 18 | 161 | 52 | (1) | 1,413 |
| Earnings per share | 21.8p | 1.5p | 0.4p | 3.2p | 1.0p | - | 27.9p |
| Weighted average number of shares (millions) | 5,064 | | | | | | 5,064 |

Income statement – Core earnings reconciliation
Three months ended 31 March 2011

| | Total results (restated) £m | Intangible amortisation £m | Intangible impairment £m | Major restructuring £m | Legal costs £m | Other operating income £m | Core results £m |
|--|--------------------------------------|----------------------------------|--------------------------------|------------------------------|----------------------|------------------------------------|-----------------------|
| Turnover | 6,585 | | | | | | 6,585 |
| Cost of sales | (1,872) | 77 | | 15 | | | (1,780) |
| Gross profit | 4,713 | 77 | | 15 | | | 4,805 |
| Selling, general and administration | (2,080) | | | 103 | | | (1,977) |
| Research and development | (915) | 34 | 8 | 17 | | | (856) |
| Royalty income | 72 | | | | | | 72 |
| Other operating income | 245 | | | | | (245) | - |
| Operating profit | 2,035 | 111 | 8 | 135 | | (245) | 2,044 |
| Net finance costs | (174) | | | | | | (174) |
| Profit on disposal of interest in associates | 584 | | | | | (584) | - |
| Share of after tax profits of associates and joint ventures | 19 | | | | | | 19 |
| Profit before taxation | 2,464 | 111 | 8 | 135 | | (829) | 1,889 |
| Taxation | (880) | (35) | (2) | (21) | | 424 | (514) |
| <i>Tax rate %</i> | 35.7% | | | | | | 27.2% |
| Profit after taxation | 1,584 | 76 | 6 | 114 | | (405) | 1,375 |
| Profit attributable to non-controlling interests | 59 | | | | | | 59 |
| Profit attributable to shareholders | 1,525 | 76 | 6 | 114 | | (405) | 1,316 |
| Earnings per share | 30.0p | 1.5p | 0.1p | 2.2p | | (7.9)p | 25.9p |
| Weighted average number of shares (millions) | 5,087 | | | | | | 5,087 |

Income statement – Core earnings reconciliation
Year ended 31 December 2010

| | Total results £m | Intangible amortisation £m | Intangible impairment £m | Major restructuring £m | Legal costs £m | Other operating income £m | Core results £m |
|--|---------------------|----------------------------------|--------------------------------|------------------------------|----------------------|------------------------------------|-----------------------|
| Turnover | 28,392 | | | | | | 28,392 |
| Cost of sales | (7,898) | 295 | 11 | 187 | | | (7,405) |
| Gross profit | 20,494 | 295 | 11 | 187 | | | 20,987 |
| Selling, general and administration | (12,747) | | | 665 | 4,001 | | (8,081) |
| Research and development | (4,457) | 133 | 126 | 493 | | | (3,705) |
| Royalty income | 296 | | | | | | 296 |
| Other operating income | 197 | | | | | (197) | - |
| Operating profit | 3,783 | 428 | 137 | 1,345 | 4,001 | (197) | 9,497 |
| Net finance costs | (715) | | | 3 | | | (712) |
| Profit on disposal of interest in associates | 8 | | | | | (8) | - |
| Share of after tax profits of associates and joint ventures | 81 | | | | | | 81 |
| Profit before taxation | 3,157 | 428 | 137 | 1,348 | 4,001 | (205) | 8,866 |
| Taxation | (1,304) | (136) | (39) | (240) | (600) | 53 | (2,266) |
| <i>Tax rate %</i> | <i>41.3%</i> | | | | | | <i>25.6%</i> |
| Profit after taxation | 1,853 | 292 | 98 | 1,108 | 3,401 | (152) | 6,600 |
| Profit attributable to non-controlling interests | 219 | | | | | | 219 |
| Profit attributable to shareholders | 1,634 | 292 | 98 | 1,108 | 3,401 | (152) | 6,381 |
| Earnings per share | 32.1p | 5.7p | 1.9p | 21.8p | 66.9p | (2.9)p | 125.5p |
| Weighted average number of shares (millions) | 5,085 | | | | | | 5,085 |